Metraipolis › archive › dc_45fcf24dd27b

HER2-Ultralow: Prevalence, Characteristics, and Treatment Choices Among Advanced Breast Cancer Patients With Tumors Initially Scored as IHC 0 — Europe PMC PMID:42340017

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42340017
DOI
10.1155/tbj/7212120
License (as archived)
solo-consultazione
Archived
2026-11-07T06:41:49.319Z
SHA-256 of the archived text
9d36fdd81dc612f51946dadbcd59b5a1de0d16648d67dac3916415c10b09e16b
Stable URL of this page
https://metraipolis.com/documento/dc_45fcf24dd27b

How to cite

HER2-Ultralow: Prevalence, Characteristics, and Treatment Choices Among Advanced Breast Cancer Patients With Tumors Initially Scored as IHC 0 — Europe PMC PMID:42340017 — Europe PMC (en), https://europepmc.org/article/MED/42340017 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_45fcf24dd27b (Metraipolis archive dc_45fcf24dd27b, sha256 9d36fdd81dc612f51946dadbcd59b5a1de0d16648d67dac3916415c10b09e16b)
BibTeX
@misc{dc45fcf24dd27b,
  title = {HER2-Ultralow: Prevalence, Characteristics, and Treatment Choices Among Advanced Breast Cancer Patients With Tumors Initially Scored as IHC 0 — Europe PMC PMID:42340017},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42340017},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_45fcf24dd27b; sha256 9d36fdd81dc612f51946dadbcd59b5a1de0d16648d67dac3916415c10b09e16b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42340017. Agents can read the archived copy with the MCP tool read_document.